OHA Investment Corporation Schedules Earnings Release and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
OHA Investment Corporation Schedules Earnings Release and Teleconference for Quarter Ended September 30, 2014

New York, Oct. 8, 2014 (GLOBE NEWSWIRE) -- OHA Investment Corporation (NASDAQ: OHAI) (the "Company") today announced that it plans to report its financial results for the quarter ended September 30, 2014 on Thursday, November 6, 2014.  In addition, representatives of the Company's new investment advisor, Oak Hill Advisors, L.P., will discuss the Company's investment strategy and future plans.

All interested persons are invited to participate in a conference call at 11:00 Eastern Time on Thursday, November 6, 2014.  Callers in the U.S. can access the conference call by dialing (877) 303-7617.  International callers can access the conference by dialing (760) 666-3609.  Callers are encouraged to dial in at least 5-10 minutes prior to the call.  The call will also be accessible via the internet, on our Investor Relations page at www.ohainvestmentcorporation.com .

About OHA Investment Corporation

OHA Investment Corporation (NASDAQ: OHAI) is a specialty finance company designed to provide its investors with current income and capital appreciation. OHAI focuses primarily on providing creative direct lending solutions to middle market private companies across industry sectors. OHAI is externally managed by Oak Hill Advisors, L.P., a leading independent investment firm ( www.oakhilladvisors.com ).  Oak Hill Advisors has deep experience in direct lending, having invested approximately $3 billion in nearly 100 direct lending investments over the past 12 years.

OHAI was formerly known as NGP Capital Resources Company prior to Oak Hill Advisors assuming the external manager role for the Company on September 30, 2014.  OHAI has elected to be regulated as a business development company, or a BDC, under the Investment Company Act of 1940.

Forward-Looking Statements

This press release may contain forward-looking statements.  We may use words such as "anticipates," "believes," "intends," "plans," "expects," "projects," "estimates," "will," "should," "may" and similar expressions to identify forward-looking statements.  These forward-looking statements are subject to various risks and uncertainties.  Certain factors could cause actual results and conditions to differ materially from those projected, including the uncertainties associated with the timing or likelihood of transaction closings, changes in interest rates, availability of transactions, the future operating results of our portfolio companies, regulatory factors, changes in regional, national, or international  economic conditions and their  impact on the industries in which we invest, other changes in the conditions of the industries in which we invest and other factors enumerated in our filings with the Securities and Exchange Commission (the "SEC").  You should not place undue reliance on such forward-looking statements, which speak only as of the date they are made.  We undertake no obligation to update our forward-looking statements made herein, unless required by law.

Persons considering an investment in OHA Investment Corporation should consider the investment objectives, risks, and charges and expenses of the Company carefully before investing.  Such information and other information about us is available in our annual report on Form 10-K, in our quarterly reports on Form 10-Q, in our current reports on Form 8-K, and in prospectuses we issue from time to time in connection with our offering of securities.  Such materials are filed with the SEC and copies are available on the SEC's website, www.sec.gov , and in the Investor Relations section of our website at www.ohainvestmentcorporation.com .  Prospective investors should read such materials carefully before investing.

CONTACTS:

For investment proposals, contact OHAI, (212) 326-1500

Steven Wayne - swayne@oakhilladvisors.com

Bob Long - blong@oakhilladvisors.com

For media inquiries, contact Kekst and Company, (212) 521-4800

Jeremy Fielding - Jeremy-Fielding@kekst.com

James David - James-David@kekst.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 114

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 317

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 7

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 172

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
Giovanni Recalde Sues County After False Report

Updated Category News Views 215

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 64

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading
OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 66

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Armada Moves up as Key Player in US SI Exports

Updated Category News Views 207

Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 122

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 26

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading

Top 5 Most Recently Viewed Articles

T-Mobile US: A Decade of Impressive Stock Growth Revealed

Updated Category News Views 142

T-Mobile US and Its Remarkable Growth Journey T-Mobile US (NASDAQ: TMUS) has shown exceptional growth over the last decade. With an annualized return rate of 20.05%, the company has outpaced the broader market by 8.22%. As of the latest information available, T-Mobile's market capitalization stands at an impressive $269.40 billion, highlighting its substantial position...

Continue Reading
Analysts Adjust TFI International's Forecasts After Q3 Report

Updated Category News Views 67

TFI International Reports Weaker-Than-Expected Q3 Earnings After the market closed on a recent Monday, TFI International (NYSE: TFII) announced its quarterly earnings figures, which unfortunately fell below expectations. The company reported earnings of $1.60 per share, compared to analyst predictions of $1.78 per share. In addition, TFI International's quarterly revenue...

Continue Reading
C3.ai Investors Face Class Action Amidst Poor Financial Results

Updated Category News Views 179

C3.ai Class Action Overview The Portnoy Law Firm is stepping forward to represent investors of C3.ai, Inc. as a class action develops. This legal move comes after concerning preliminary financial results announced by the company. Investors who purchased securities of C3 during the specified class period are encouraged to engage with the firm. Details of the Legal Class...

Continue Reading
21st.BIO Seeks EU Nod for Precision Fermentation Tech

Updated Category News Views 172

Is Precision Fermentation Europe's Next Big Bet? Here we go again with another tech trying to revolutionize the food industry, and this time it's the Danish company 21st.BIO making strides in Europe. They've tossed their hat in the ring with an EU Novel Food application for BLG Essential+™, hoping to weave precision fermentation into the fabric of European food...

Continue Reading
Key Pfizer Executives Support Current Leadership Amid Challenges

Updated Category News Views 105

Support for Pfizer's Leadership from Former Executives In a recent statement, former Pfizer executives, Ian Read and Frank D'Amelio, clarified their stance regarding the ongoing campaign by activist investor Starboard Value. They emphasized that they will not be engaging with Starboard, which has been advocating for changes within the pharmaceutical giant to enhance its...

Continue Reading